Full text is available at the source.
Association of long-term weight management pharmacotherapy with multiple health outcomes: an umbrella review and evidence map
Links between long-term weight loss drugs and various health results: a summary and overview
AI simplified
Abstract
Sixteen meta-analyses of 235 randomized clinical trials revealed that 88% of associations between six pharmacotherapies and health outcomes were statistically significant.
- The pharmacotherapies evaluated include orlistat, liraglutide, phentermine/topiramate, naltrexone/bupropion, semaglutide, and tirzepatide.
- Significant beneficial outcomes were observed for body weight, weight loss, waist circumference, body mass index, total cholesterol, triglycerides, cholesterol types, blood pressure, and glycemic profile.
- Weight loss and partial improvements in lipid profiles, blood pressure, and glycemic control are associated with these pharmacotherapies among individuals with overweight or obesity.
- Adverse events were notably associated with liraglutide, naltrexone/bupropion, semaglutide, and orlistat.
- The quality of the included meta-analyses indicates a need for improvement.
AI simplified